These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 230108)

  • 1. Antibody to poliovirus in older children and young adults in Israel and the use of poliovaccines for the immunization of the seronegatives.
    Goldblum N; Kra-Oz Z; Swartz T
    Dev Biol Stand; 1979; 43():173-7. PubMed ID: 230108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poliomyelitis vaccines in Belgium: 20 years of experience.
    Andre FE
    Dev Biol Stand; 1979; 43():187-93. PubMed ID: 230109
    [No Abstract]   [Full Text] [Related]  

  • 3. [Vaccination against poliomyelitis. Formation of immunity evaluated according to the results of serological surveys].
    Zabicka J
    Przegl Epidemiol; 1981; 35(3):385-9. PubMed ID: 6276928
    [No Abstract]   [Full Text] [Related]  

  • 4. [Poliomyelitis vaccination in Denmark].
    Petersen I
    Ugeskr Laeger; 1985 Jan; 147(4):265-9. PubMed ID: 3976028
    [No Abstract]   [Full Text] [Related]  

  • 5. The problems of poliovirus immunization.
    Fulginiti VA
    Hosp Pract; 1980 Aug; 15(8):61-7. PubMed ID: 6249713
    [No Abstract]   [Full Text] [Related]  

  • 6. Antipolio prophylaxis of immunocompromised children during a nationwide oral poliovaccine campaign.
    Stenvik M; Hovi L; Siimes MA; Roivainen M; Hovi T
    Pediatr Infect Dis J; 1987 Dec; 6(12):1106-10. PubMed ID: 2829105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Criteria for control of infectious diseases with poliomyelitis as an example.
    Evans AS
    Prog Med Virol; 1984; 29():141-65. PubMed ID: 6322231
    [No Abstract]   [Full Text] [Related]  

  • 8. Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel.
    Swartz TA; Green MS; Handscher R; Sofer D; Cohen-Dar M; Shohat T; Habib S; Barak E; Dror Z; Somekh E; Peled-Leviathan T; Yulzari R; Libling A; Mendelson E; Shulman LM
    Vaccine; 2008 Feb; 26(8):1083-90. PubMed ID: 18241962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral poliovaccine: will it help eradicate polio or cause the next epidemic?
    Shulman LM; Manor Y; Sofer D; Swartz T; Mendelson E
    Isr Med Assoc J; 2006 May; 8(5):312-5. PubMed ID: 16805227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody status to poliomyelitis, measles, rubella, diphtheria and tetanus, Ontario, 1969-70: deficiencies discovered and remedies required.
    MacLeod DR; Ing WK; Belcourt RJ; Pearson EW; Bell JS
    Can Med Assoc J; 1975 Oct; 113(7):619-23. PubMed ID: 1181016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and risks of attenuated polio vaccine strains in a community immunized with inactivated polio vaccine.
    Rossier E; Phipps PH; Pépin O
    Dev Biol Stand; 1979; 43():179-85. PubMed ID: 520669
    [No Abstract]   [Full Text] [Related]  

  • 12. [Worldwide eradication of poliomyelitis].
    Rasch G; Schreier E; Kiehl W; Kurth R
    Wien Klin Wochenschr; 2001 Oct; 113(20-21):839-45. PubMed ID: 11732120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Findings on the success of vaccination and revaccination with live and inactivated vaccines against poliomyelitis].
    Dostal V; Haenzel I; Sturm W
    Schweiz Med Wochenschr; 1969 Sep; 99(37):1322-4. PubMed ID: 4309326
    [No Abstract]   [Full Text] [Related]  

  • 14. Poliovirus antibodies in age groups: an assessment of obligatory vaccination in Belgium.
    Lamy ME; Cornu C; Desmyter J
    Dev Biol Stand; 1979; 43():207-13. PubMed ID: 230111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The natural history of poliomyelitis in Israel, 1949-1982.
    Goldblum N; Swartz T; Gerichter CB; Handsher R; Lasch EE; Melnick JL
    Prog Med Virol; 1984; 29():115-23. PubMed ID: 6366916
    [No Abstract]   [Full Text] [Related]  

  • 16. [A comparison of the effectiveness of mass immunization campaign of trivalent oral poliovirus vaccine (TOPV) by epidemiological serosurvey. Shandong Collaborating Group for Poliomyelitis Control and Surveillance, Jinan, Shandong].
    Xu A
    Zhonghua Liu Xing Bing Xue Za Zhi; 1992 Oct; 13(5):261-4. PubMed ID: 1338626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes.
    Richardson G; Linkins RW; Eames MA; Wood DJ; Campbell PJ; Ankers E; Deniel M; Kabbaj A; Magrath DI; Minor PD
    Bull World Health Organ; 1995; 73(6):769-77. PubMed ID: 8907770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poliomyelitis vaccination. Evaluation and direction in continuing application.
    Sabin AB
    Am J Clin Pathol; 1978 Jul; 70(1 Suppl):136-40. PubMed ID: 210653
    [No Abstract]   [Full Text] [Related]  

  • 19. [Revaccination by oral monovalent poliovaccine type 3 (author's transl)].
    Srámová H; Teplý V; Bernatziková V
    Cesk Epidemiol Mikrobiol Imunol; 1981 Mar; 30(2):95-100. PubMed ID: 6261973
    [No Abstract]   [Full Text] [Related]  

  • 20. Poliomyelitis outbreak in Israel in 1988: a report with two commentaries.
    Slater PE; Orenstein WA; Morag A; Avni A; Handsher R; Green MS; Costin C; Yarrow A; Rishpon S; Havkin O
    Lancet; 1990 May; 335(8699):1192-5; discussion 1196-8. PubMed ID: 1971043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.